Houlihan Lokey (HLI) Form 144 Reveals Proposed 6,811-Share Sale
Rhea-AI Filing Summary
Houlihan Lokey (HLI) Form 144 summary: An insider filed a notice to sell 6,811 common shares on or about 09/16/2025 through Morgan Stanley Smith Barney on the NYSE, with an aggregate market value reported at $1,380,898.92. The shares were acquired on 05/15/2025 as restricted stock that vested under a registered plan tied to services rendered.
The filing also reports a prior sale by the IRWIN N GOLD FAMILY TRUST of 5,000 shares on 06/30/2025 for gross proceeds of $914,028.50. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Positive
- None.
Negative
- Insider sale notice: Proposed sale of 6,811 shares with aggregate market value of $1,380,898.92, which may be viewed negatively by some investors
- Recent prior sale: IRWIN N GOLD FAMILY TRUST sold 5,000 shares on 06/30/2025 for $914,028.50
Insights
TL;DR: Insider plans to sell vested restricted shares worth about $1.38M; prior sale of 5,000 shares realized $914K.
The Form 144 notifies the market of a proposed sale of 6,811 common shares scheduled for approximately 09/16/2025 through Morgan Stanley Smith Barney, with an indicated aggregate market value of $1,380,898.92. The shares originated from a restricted stock vesting event on 05/15/2025, tied to services rendered, which is a common executive compensation mechanism. The filing also discloses a recent sale by the IRWIN N GOLD FAMILY TRUST of 5,000 shares on 06/30/2025 for $914,028.50. For investors, these are routine insider-sale disclosures required for compliance and do not, by themselves, provide information about company performance.
TL;DR: Disclosure aligns with Rule 144 requirements; transaction appears to be vesting-driven, not an open-market planned disposition detail.
The notice shows restricted stock vesting as the acquisition event and lists the intended broker and exchange for sale. The filer attests no undisclosed material adverse information. The filing does not state a trading plan or 10b5-1 adoption date, so the sale appears to be a standard post-vesting disposition subject to Rule 144 timing and volume constraints. From a governance standpoint, this is a standard compliance disclosure rather than an indicator of corporate governance issues.